Pagaya Reiterates Funding Strategy at Morgan Stanley Conference, But Unit Economics Remain Unproven

What happened

Pagaya Technologies presented at the Morgan Stanley Technology, Media & Telecom Conference, likely highlighting its AI-driven lending network and recent capital markets execution, including the upsized $800 million ABS deal with 32 investors. Management probably emphasized the shift towards revolving funding structures and forward-flow commitments to enhance funding durability and reduce volatility. However, this presentation comes against a backdrop of negative capital markets execution fees in Q4 2025, signaling persistent spread pressure that directly erodes profitability, as detailed in recent filings. The transcript did not appear to provide new, tangible data on credit reserves or execution fee recovery, leaving core investor concerns about economics unaddressed. Thus, the event reinforces the existing narrative that Pagaya must convert its ABS access into positive unit economics before the investment case strengthens.

Implication

Pagaya's conference appearance underscores its continued dependence on favorable ABS markets, which have recently shown stress through negative execution fees and allowance builds, capping near-term upside. Without concrete updates on execution fees turning positive or credit reserves stabilizing, the stock's downside risks—such as spread widening and capital strain from risk retention—remain elevated and unmitigated. The company's efforts to diversify funding through revolving structures are aspirational but lack demonstrated utilization, making them unreliable catalysts until evidenced in filings. Therefore, patience is warranted to monitor the next 10-Q for key metrics like capital markets execution fees and allowance trends, which are decisive for the thesis. Any failure to show improvement in these areas by the 3-6 month re-assessment window could validate the bear case and drive prices toward $7, while success might support a move to $13-$18.

Thesis delta

The presentation did not shift the investment thesis, as it likely reiterated known strategies without providing new, verifiable data on profitability or credit health. Pagaya still needs to demonstrate that it can access ABS markets at profitable clearing levels, not just maintain issuance volume, to change the WAIT rating. Until quarterly filings confirm positive execution fees and stable allowances, the thesis remains anchored on observable proof rather than managerial optimism.